A Phase 3 interventional study of Eculizumab in Atypical Hemolytic Uremic, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 6 sites in China. Open to participants aged 0 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-12-08.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase 3b, open-label, single-arm, multicenter study to evaluate the efficacy and safety of eculizumab in participants with atypical hemolytic uremic syndrome (aHUS) in China
This is a Phase 3b, open-label, single-arm, multicenter study to evaluate the efficacy and safety of eculizumab in participants with aHUS in China. The study will be conducted in participants of any age who weigh ≥ 5 kg and who previously have not been treated with complement inhibitors. The study consists of an up to 7-day Screening Period and a 26-week Treatment Period. An 8-week Safety Follow-up Phone Call will be required only for participants who discontinue eculizumab treatment during the study or for participants who will not receive continued access to eculizumab after completing study treatment. Approximately 25 eligible participants in China will be enrolled.
Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Eculizumab in a single dose vial.
Drug: Eculizumab
Weight-based doses of Eculizumab will be administered intravenously as an induction dose followed by maintenance dose at Day 8, 15, or 29 depending on weight; then every 2 or 3 weeks, depending upon weight.
Percentage of Participants With a Complete Thrombotic Microangiopathy (TMA) Response
The criteria for complete TMA response were: 1. Normalization of platelet count (defined as platelet count ≥ 150000/microliter (ul). 2. Normalization of lactate dehydrogenase (LDH, defined as LDH ≤ upper limit of normal \[ULN\]). 3. ≥ 25% improvement in serum creatinine from baseline.
Time frame: Up to Week 26
Number of Participants With an Adverse Event (AE)
An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. A serious AE (SAE) was defined as any untoward medical occurrence that, at any dose: * resulted in death, * was life-threatening, * required inpatient hospitalization or prolongation of existing hospitalization, * resulted in persistent disability/incapacity, * was a congenital anomaly/birth defect, or * was an important medical event. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Adverse Events' Section.
Time frame: Up to Week 34
Mean Serum Concentration of Eculizumab
Time frame: Pre-dose and post-dose at Days 1, 8, 29, 85, and 141; Pre-dose at Day 183
Change From Baseline in Serum Free Complement 5 (C5)
Time frame: Baseline (Day 1 pre-dose) to Days 1, 8, 29, 85 and 141 (pre-dose and post-dose) and pre-dose at Day 183
Change From Baseline in Serum Total C5
Time frame: Baseline (Day 1 pre-dose) to Days 1, 8, 29, 85 and 141 (pre-dose and post-dose) and pre-dose at Day 183
Number of Participants With an Anti-drug Antibody (ADA) Response
An ADA response was defined as a positive ADA sample at any time during the study.
Time frame: Up to Week 26
Time to Complete TMA Response
Time to complete TMA response was defined as the time from first infusion to the first time point at which all criteria for complete TMA response was met. The criteria for complete TMA response were: 1. Normalization of platelet count (defined as platelet count ≥ 150000/ul. 2. Normalization of LDH, defined as LDH ≤ ULN). 3. ≥ 25% improvement in serum creatinine from baseline. Participants who did not have a response were censored at the date of last visit or study discontinuation at the time when the analysis was performed.
Time frame: Up to Week 26
Proportion of Participants On or Off Dialysis at Each Timepoint
Participants were considered as 'off' dialysis at a specific time point if they were dialysis free for more than 5 days prior to that time point. Participants were considered as 'on' dialysis at a specific time point if they were dialysis free to 5 days or less up prior to that time point.
Time frame: Baseline and Days 22, 43, 71, 99, 113, 127, 155 and 183
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Each Scheduled Visit
Expressed in milliliters per minute per 1.73 square meters of body surface area.
Time frame: Baseline, Days 22, 43, 71, 99, 113, 127, 155 and 183
Proportion of Participants With a Chronic Kidney Disease (CKD) Stage Shift Categorized as "Improved", "Stable", or "Worsened" at Each Scheduled Visit Compared to Baseline
CKD stage was classified based on the National Kidney Foundation Chronic Kidney Disease Stage where Stage 5 represents the most severe disease and Stage 1 represents the least severe disease. "Improved" excluded participants with Stage 1 at baseline as there was no room for improvement. "Worsened" excludes participants with Stage 5 at baseline as there was no room to worsen.
Time frame: Baseline to Days 22, 43, 71, 99, 113, 127, 155 and 183
Change From Baseline in Platelets
Platelet values obtained from the day of a blood transfusion of platelets through 3 days after the transfusion are excluded from all analysis.
Time frame: Baseline, Days 22, 43, 71, 99, 113, 127, 155, and 183
Change From Baseline in LDH
Time frame: Baseline, Days 22, 43, 71, 99, 113, 127, 155, and 183
Change From Baseline in Hemoglobin
Hemoglobin values obtained from the day of a blood transfusion of either whole blood or packed red blood cells through 7 days after the transfusion are excluded from all analysis.
Time frame: Baseline, Days 22, 43, 71, 99, 113, 127, 155, and 183
| Milestone | Eculizumab |
|---|---|
| Started | 25 |
| Received at least 1 dose of study drug | 25 |
| Completed | 22 |
| Not completed | 3 |
| Withdrew: Other than specified | 2 |
| Withdrew: Study specific discontinuation criteria | 1 |
The criteria for complete TMA response were: 1. Normalization of platelet count (defined as platelet count ≥ 150000/microliter (ul). 2. Normalization of lactate dehydrogenase (LDH, defined as LDH ≤ upper limit of normal \[ULN\]). 3. ≥ 25% improvement in serum creatinine from baseline.
| percentage of participants | Eculizumab |
|---|---|
| Percentage of Participants With a Complete Thrombotic Microangiopathy (TMA) Response | 64.0 ± 42.5 |
An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. A serious AE (SAE) was defined as any untoward medical occurrence that, at any dose: * resulted in death, * was life-threatening, * required inpatient hospitalization or prolongation of existing hospitalization, * resulted in persistent disability/incapacity, * was a congenital anomaly/birth defect, or * was an important medical event. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Adverse Events' Section.
| Participants | Eculizumab |
|---|---|
| Any AE | 24 |
| Any SAE | 8 |
| micrograms per milliliter (ug/mL) | Eculizumab |
|---|---|
| Day 1: Pre-dose | 4.690 ± 0.00 |
| Day 1: Post-dose | 373.423 ± 47.59 |
| Day 8: Pre-dose | 153.190 ± 69.69 |
| Day 8: Post-dose | 498.262 ± 41.18 |
| Day 29: Pre-dose | 353.726 ± 36.96 |
| Day 29: Post-dose | 727.862 ± 32.22 |
| Day 85: Pre-dose | 360.070 ± 43.89 |
| Day 85: Post-dose | 728.624 ± 42.04 |
| Day 141: Pre-dose | 433.737 ± 41.32 |
| Day 141: Post-dose | 883.675 ± 38.74 |
| Day 183: Pre-dose | 434.739 ± 38.66 |
| ug/mL | Eculizumab |
|---|---|
| Day 1: Post-dose | -79.8842 ± 17.5197 |
| Day 8: Pre-dose | -79.6539 ± 17.8589 |
| Day 8: Post-dose | -79.6636 ± 17.8610 |
| Day 29: Pre-dose | -80.4277 ± 17.1241 |
| Day 29: Post-dose | -80.4284 ± 17.1241 |
| Day 85: Pre-dose | -80.0632 ± 17.3489 |
| Day 85: Post-dose | -80.0632 ± 17.3489 |
| Day 141: Pre-dose | -80.0625 ± 17.3485 |
| Day 141: Post-dose | -80.0632 ± 17.3489 |
| Day 183: Pre-dose | -80.0632 ± 17.3489 |
| ug/mL | Eculizumab |
|---|---|
| Day 1: Post-dose | -12.0267 ± 6.1396 |
| Day 8: Pre-dose | 37.9293 ± 21.3162 |
| Day 8: Post-dose | 40.2831 ± 23.0175 |
| Day 29: Pre-dose | 65.9100 ± 25.0734 |
| Day 29: Post-dose | 64.4783 ± 22.7695 |
| Day 85: Pre-dose | 71.2418 ± 25.7350 |
| Day 85: Post-dose | 66.5267 ± 26.7232 |
| Day 141: Pre-dose | 71.8284 ± 25.3689 |
| Day 141: Post-dose | 67.0693 ± 23.1231 |
| Day 183: Pre-dose | 78.5497 ± 27.1158 |
An ADA response was defined as a positive ADA sample at any time during the study.
| Participants | Eculizumab |
|---|---|
| Number of Participants With an Anti-drug Antibody (ADA) Response | 0 |
Time to complete TMA response was defined as the time from first infusion to the first time point at which all criteria for complete TMA response was met. The criteria for complete TMA response were: 1. Normalization of platelet count (defined as platelet count ≥ 150000/ul. 2. Normalization of LDH, defined as LDH ≤ ULN). 3. ≥ 25% improvement in serum creatinine from baseline. Participants who did not have a response were censored at the date of last visit or study discontinuation at the time when the analysis was performed.
| days | Eculizumab |
|---|---|
| Time to Complete TMA Response | 75.0 (22.0 to NA) |
Participants were considered as 'off' dialysis at a specific time point if they were dialysis free for more than 5 days prior to that time point. Participants were considered as 'on' dialysis at a specific time point if they were dialysis free to 5 days or less up prior to that time point.
| proportion of participants | Eculizumab |
|---|---|
| Baseline: On Dialysis | 0.440 (0.244 to 0.651) |
| Baseline: Off Dialysis | 0.560 (0.349 to 0.756) |
| Day 22: On Dialysis | 0.261 (0.102 to 0.484) |
| Day 22: Off Dialysis | 0.739 (0.516 to 0.898) |
| Day 43: On Dialysis | 0.235 (0.068 to 0.499) |
| Day 43: Off Dialysis | 0.765 (0.501 to 0.932) |
| Day 71: On Dialysis | 0.211 (0.061 to 0.456) |
| Day 71: Off Dialysis | 0.789 (0.544 to 0.939) |
| Day 99: On Dialysis | 0.176 (0.038 to 0.434) |
| Day 99: Off Dialysis | 0.824 (0.566 to 0.962) |
| Day 113: On Dialysis | 0.167 (0.036 to 0.414) |
| Day 113: Off Dialysis | 0.833 (0.586 to 0.964) |
| Day 127: On Dialysis | 0.111 (0.014 to 0.347) |
| Day 127: Off Dialysis | 0.889 (0.653 to 0.986) |
| Day 155: On Dialysis | 0.167 (0.036 to 0.414) |
| Day 155: Off Dialysis | 0.833 (0.586 to 0.964) |
| Day 183: On Dialysis | 0.167 (0.036 to 0.414) |
| Day 183: Off Dialysis | 0.833 (0.586 to 0.964) |
Expressed in milliliters per minute per 1.73 square meters of body surface area.
| mL/min/1.73^2 | Eculizumab |
|---|---|
| Day 22 | 39.82 ± 50.83 |
| Day 43 | 32.72 ± 44.75 |
| Day 71 | 40.33 ± 47.38 |
| Day 99 | 37.53 ± 47.17 |
| Day 113 | 35.88 ± 45.38 |
| Day 127 | 35.85 ± 48.01 |
| Day 155 | 43.33 ± 49.32 |
| Day 183 | 36.29 ± 44.21 |
CKD stage was classified based on the National Kidney Foundation Chronic Kidney Disease Stage where Stage 5 represents the most severe disease and Stage 1 represents the least severe disease. "Improved" excluded participants with Stage 1 at baseline as there was no room for improvement. "Worsened" excludes participants with Stage 5 at baseline as there was no room to worsen.
| proportion of participants | Eculizumab |
|---|---|
| Day 22: Improved | 0.545 (0.322 to 0.756) |
| Day 22: Stable | 0.455 (0.244 to 0.678) |
| Day 22: Worsened | 0 (0 to 0.410) |
| Day 43: Improved | 0.688 (0.413 to 0.890) |
| Day 43: Stable | 0.313 (0.110 to 0.587) |
| Day 43: Worsened | 0 (0 to 0.602) |
| Day 71: Improved | 0.722 (0.465 to 0.903) |
| Day 71: Stable | 0.278 (0.097 to 0.535) |
| Day 71: Worsened | 0 (0 to 0.522) |
| Day 99: Improved | 0.750 (0.476 to 0.927) |
| Day 99: Stable | 0.250 (0.073 to 0.524) |
| Day 99: Worsened | 0 (0 to 0.522) |
| Day 113: Improved | 0.765 (0.501 to 0.932) |
| Day 113: Stable | 0.235 (0.068 to 0.499) |
| Day 113: Worsened | 0 (0 to 0.459) |
| Day 127: Improved | 0.765 (0.501 to 0.932) |
| Day 127: Stable | 0.235 (0.068 to 0.499) |
| Day 127: Worsened | 0 (0 to 0.459) |
| Day 155: Improved | 0.875 (0.617 to 0.984) |
| Day 155: Stable | 0.125 (0.016 to 0.383) |
| Day 155: Worsened | 0 (0 to 0.522) |
| Day 183: Improved | 0.824 (0.566 to 0.962) |
| Day 183: Stable | 0.176 (0.038 to 0.434) |
| Day 183: Worsened | 0 (0 to 0.522) |
Platelet values obtained from the day of a blood transfusion of platelets through 3 days after the transfusion are excluded from all analysis.
| 10^9 platelets/liter (L) | Eculizumab |
|---|---|
| Day 22 | 76.5 ± 117.7 |
| Day 43 | 65.5 ± 90.1 |
| Day 71 | 71.3 ± 97.9 |
| Day 99 | 79.4 ± 68.1 |
| Day 113 | 60.1 ± 82.7 |
| Day 127 | 61.8 ± 86.1 |
| Day 155 | 76.8 ± 98.2 |
| Day 183 | 80.3 ± 98.0 |
| microkatal per liter (ukat/L) | Eculizumab |
|---|---|
| Day 22 | -9.445 ± 12.459 |
| Day 43 | -6.147 ± 10.175 |
| Day 71 | -7.083 ± 10.099 |
| Day 99 | -5.861 ± 8.356 |
| Day 113 | -5.769 ± 8.041 |
| Day 127 | -5.444 ± 8.314 |
| Day 155 | -5.848 ± 8.478 |
| Day 183 | -5.680 ± 8.172 |
Hemoglobin values obtained from the day of a blood transfusion of either whole blood or packed red blood cells through 7 days after the transfusion are excluded from all analysis.
| grams per liter (g/L) | Eculizumab |
|---|---|
| Day 22 | 17.0 ± 18.3 |
| Day 43 | 25.7 ± 20.1 |
| Day 71 | 30.5 ± 22.6 |
| Day 99 | 30.3 ± 19.3 |
| Day 113 | 29.8 ± 17.8 |
| Day 127 | 25.2 ± 16.4 |
| Day 155 | 30.5 ± 14.9 |
| Day 183 | 36.2 ± 15.8 |
Collected over Up to Week 34. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eculizumab | 0/25 (0%) | 8/25 (32%) | 24/25 (96%) |
| Event | Eculizumab |
|---|---|
| PneumoniaInfections and infestations | 2/25 |
| Bacterial infectionInfections and infestations | 1/25 |
| Clostridium difficile infectionInfections and infestations | 1/25 |
| InfectionInfections and infestations | 1/25 |
| Rotavirus infectionInfections and infestations | 1/25 |
| RetchingGastrointestinal disorders | 1/25 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 1/25 |
| Hepatic function abnormalHepatobiliary disorders | 1/25 |
| Synovial cystMusculoskeletal and connective tissue disorders | 1/25 |
| Event | Eculizumab |
|---|---|
| HyperkalaemiaMetabolism and nutrition disorders | 7/25 |
| Upper respiratory tract infectionInfections and infestations | 5/25 |
| VomitingGastrointestinal disorders | 5/25 |
| Respiratory tract infectionInfections and infestations | 4/25 |
| Hepatic function abnormalHepatobiliary disorders | 4/25 |
| InfectionInfections and infestations | 3/25 |
| HyperphosphataemiaMetabolism and nutrition disorders | 3/25 |
| PyrexiaGeneral disorders | 3/25 |
| BronchitisInfections and infestations | 2/25 |
| InfluenzaInfections and infestations | 2/25 |
Full Analysis Set: Included all participants who received at least 1 dose of study intervention and had at least 1 efficacy assessment post first dose.
| Age, Continuous(years) | Eculizumab |
|---|---|
| Mean | 23.40 ± 15.95 |
| Age, Customized(Participants) | Eculizumab |
|---|---|
| In utero | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 2 |
| Children (2-11 years) | 7 |
| Adolescents (12-17 years) | 2 |
| Adults (18-64 years) | 14 |
| From 65-84 years | 0 |
| 85 years and over | 0 |
| Sex: Female, Male(Participants) | Eculizumab |
|---|---|
| Female | 6 |
| Male | 19 |
| Ethnicity (NIH/OMB)(Participants) | Eculizumab |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 24 |
| Unknown or Not Reported | 1 |
| Race (NIH/OMB)(Participants) | Eculizumab |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 25 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Jul 2023 to primary completion in May 2025, 21 months.
Results were first posted in Dec 2025, 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eculizumab
Alexion Pharmaceuticals, Inc. →